MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Standardized Field Test for Marijuana Impairment II

Phase 1
Active, not recruiting
Conditions
Marijuana Impairment
Interventions
First Posted Date
2021-11-10
Last Posted Date
2025-04-02
Lead Sponsor
Yale University
Target Recruit Count
32
Registration Number
NCT05115513
Locations
🇺🇸

Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States

Evaluation of Oral THC and CBD in Men and Women

Phase 1
Not yet recruiting
Conditions
Drug Abuse
Intoxication by Drug
Impairment
Interventions
First Posted Date
2021-10-05
Last Posted Date
2025-04-06
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
22
Registration Number
NCT05067387
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

Safety and Efficacy of Oral Cannabis in Chronic Spine Pain

Phase 3
Not yet recruiting
Conditions
Back Pain
Neck Pain
Interventions
Drug: THC/CBD
Drug: Placebo
First Posted Date
2021-09-22
Last Posted Date
2023-01-10
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
157
Registration Number
NCT05052541
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Phase 2
Recruiting
Conditions
Osteoarthritis, Knee
Osteoarthritis of the Knee
Interventions
First Posted Date
2021-08-05
Last Posted Date
2024-07-29
Lead Sponsor
Steven E Harte, PhD
Target Recruit Count
200
Registration Number
NCT04992624
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Phase 3
Completed
Conditions
Chronic Non-specific Low Back Pain
Interventions
Other: Placebo
First Posted Date
2021-06-28
Last Posted Date
2024-04-08
Lead Sponsor
Vertanical GmbH
Target Recruit Count
820
Registration Number
NCT04940741
Locations
🇩🇪

Emovis GmbH, Berlin, Germany

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-06-18
Last Posted Date
2022-07-14
Lead Sponsor
Vertanical GmbH
Target Recruit Count
42
Registration Number
NCT04930809
Locations
🇦🇹

University of Medicine in Vienna - Department of Clinical Pharmacology, Vienna, Austria

Food Effect Study of VER-01 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-06-18
Last Posted Date
2022-11-28
Lead Sponsor
Vertanical GmbH
Target Recruit Count
18
Registration Number
NCT04930796
Locations
🇦🇹

University of Medicine in Vienna - Department of Clinical Pharmacology, Vienna, Austria

In Vivo Study of THC-induced Immune-genome Changes At Single Cell Solution in HIV-infected Humans

Phase 1
Recruiting
Conditions
Healthy
HIV Infections
Interventions
First Posted Date
2021-06-10
Last Posted Date
2025-03-10
Lead Sponsor
Yale University
Target Recruit Count
40
Registration Number
NCT04920539
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

Early Phase 1
Recruiting
Conditions
HIV-1-infection
Interventions
First Posted Date
2021-05-12
Last Posted Date
2024-07-03
Lead Sponsor
University of California, San Diego
Target Recruit Count
138
Registration Number
NCT04883255
Locations
🇺🇸

UC San Diego Medical Center-Hillcrest, San Diego, California, United States

The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories

Not Applicable
Active, not recruiting
Conditions
Intrusive Memories
Interventions
Drug: Placebo
First Posted Date
2021-05-04
Last Posted Date
2025-03-10
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
291
Registration Number
NCT04871269
Locations
🇩🇪

Charité - Universitätsmedizin Berlin, Berlin-Steglitz, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath